Portfolio Companies News
May 23, 2019Targovax to fully focus on ONCOS on...
Oslo, Norway, 23 May 2019 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that going forward the company will strengthen the commitment to oncolytic viruses and focus resources to advance the... read more
May 23, 2019Targovax announces median and three...
Oslo, Norway, 23 May 2019 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces median overall survival of 33.3 months and 38% three-year survival rate in the 32-patient phase I/II clinical trial ... read more
May 23, 2019Nordic Nanovector ASA - Results for...
Oslo, Norway, 23 May 2019 Nordic Nanovector ASA (OSE: NANO) announces its results for the first quarter 2019. A presentation by the company’s senior management team will take place today in Oslo at 08:30 CEST, see details below. Eduardo Bravo, CEO, commented: “As we advance th... read more
May 21, 2019MIPS acquires patent rights and the...
May 21, 2019 MIPS, the world leader in brain protection systems within helmet-based safety, has today entered into an acquisition agreement for assets that further enhances MIPS’ product offering and safety solutions. The acquisition comprises the brand FLUID and related patent rights a... read more
May 21, 2019Nordic Nanovector: Archer-1 phase 1...
Oslo, Norway, 21 May 2019 Nordic Nanovector ASA (OSE: NANO) announces that following a safety review of the first patients in the ongoing Archer-1 (LYMRIT 37-07) trial investigating Betalutin® (177Lu-satetraxetan-lilotomab) in combination with rituximab (RTX) in second-line follicular ... read more
May 10, 2019Q1 2019 General Market Overview
Since the start in 1996, HealthCap funds have invested in 113 portfolio companies.
42 of the portfolio companies have been taken public on nine different markets.
25 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.